NASDAQ: MDXHMdxhealth Sa Stock
$1.60+0.00 (+0%)
Updated Apr 21, 2025
MDXH Price
$1.60
Fair Value Price
N/A
Market Cap
$7.92M
52 Week Low
$1.35
52 Week High
$3.50
P/E
-0.14x
P/B
0.53x
P/S
0.07x
PEG
N/A
Dividend Yield
N/A
Revenue
$90.05M
Earnings
-$38.07M
Gross Margin
61.2%
Operating Margin
-24.84%
Profit Margin
-42.3%
Debt to Equity
9.6
Operating Cash Flow
-$19M
Beta
0.43
Next Earnings
May 3, 2025
Ex-Dividend
N/A
Next Dividend
N/A
MDXH Overview
MDxHealth SA (formerly OncoMethylome Sciences SA) provides urologic solutions in the U.S. and internationally. OFferings include SelectMDx (a prostate cancer genomic testing solution), a non-invasive urine test, and ConfirmMDx, an epigenetic test that provide a clinical pathway to identify clinically prostate cancer using mimimally invasive procedures. MDxHealth was incorporated in 2003 and is headquartered in Herstal, Belgium.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine MDXH's potential to beat the market
- MDXH doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important MDXH news, forecast changes, insider trades & much more!
MDXH News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MDXH scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MDXH is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
MDXH is good value based on its book value relative to its share price (0.53x), compared to the US Diagnostics & Research industry average (3.22x)
P/B vs Industry Valuation
MDXH is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more MDXH due diligence checks available for Premium users.
Valuation
MDXH price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.14x
Industry
35.03x
Market
27.14x
MDXH price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.53x
Industry
3.22x
MDXH is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MDXH's financial health
Profit margin
Revenue
$24.7M
Net Income
-$6.8M
Profit Margin
-27.7%
MDXH's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
MDXH's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$157.3M
Liabilities
$142.5M
Debt to equity
9.6
MDXH's short-term assets ($66.90M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MDXH's long-term liabilities ($99.83M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MDXH's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
MDXH's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.1M
Investing
-$229.0k
Financing
$884.0k
MDXH's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MDXH vs Diagnostic & Research Stocks
Mdxhealth Sa Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.